Copyright
©The Author(s) 2021.
World J Hepatol. Jul 27, 2021; 13(7): 804-814
Published online Jul 27, 2021. doi: 10.4254/wjh.v13.i7.804
Published online Jul 27, 2021. doi: 10.4254/wjh.v13.i7.804
Class of agents | Type | Specific agents | Duration of action |
Antiplatelets | |||
Thienopyridines | Clopidogrel (Plavix), ticlopidine (Panardine), prasugrel (Effient), ticagrelor (Brilinta) | 5-7 d1 | |
Type III PDE inhibitor | Cilostazol (Pretal) | 2 d | |
Acetylsalicylic acid | Aspirin | 7-10 d | |
Other NSAIDs | Ibuprofen (Brufen, Advil), loxoprofen (Loxonin), diclofenac (Voltaren) etc. | Varies | |
Anticoagulants | |||
Heparin (unfractionated) | Heparin | 1-2 h | |
Heparin (LMWH) | Dalteparin (Fragmin iv), enoxaparin (Clexane, s.c.), nadroparin (s.c.) | 6-12 h2 | |
Vitamin K antagonist | Warfarin (Coumadin) | 5 d | |
Factor Xa inhibitor (s.c.) | Fondaparinux (Arixtra) | 1-1.5 d | |
DOACs | |||
Direct thrombin inhibitor | Dabigatran (Pradaxa) | 1-2 d | |
Factor Xa inhibitors | Rivaroxaban (Xarelto), apixaban (Eliquis), edoxaban (Lixiana) | 1-2 d |
- Citation: Fujikawa T. Safety of liver resection in patients receiving antithrombotic therapy: A systematic review of the literature. World J Hepatol 2021; 13(7): 804-814
- URL: https://www.wjgnet.com/1948-5182/full/v13/i7/804.htm
- DOI: https://dx.doi.org/10.4254/wjh.v13.i7.804